|This Slide: #37 of 83|
Slide #37. Oxygen Biotherapeutics — Phyxius Pharma Assets
Oxygen Biotherapeutics (OXBT)
Phyxius Pharma Assets
Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a developer of oxygen-carrying therapeutics, today announced the closing of its acquisition of certain assets of Phyxius Pharma, a privately-held biopharmaceutical company focused on the development and near-term commercialization of levosimendan to prevent and treat cardiac surgery patients at risk for developing low cardiac output syndrome (LCOS), a significant unmet medical need. Pursuant to the previously announced Purchase Agreement, Oxygen Biotherapeutics acquired the exclusive rights to develop and commercialize levosimendan in North America, and will welcome three key Phyxius Pharma executives into its management team.
Oxygen Biotherapeutics is engaged in developing biotechnology products with a focus on oxygen delivery to specific target tissues. Co. is developing Oxycyte®, a systemic perfluorocarbon product for use in situations of acute ischemia, which is in clinical trial for the treatment of traumatic brain injury. Co. is also developing its topical products: Dermacyte® line of topical cosmetic products for skin health and other cosmetic benefits; and Wundecyte™ gel developed under a contract agreement with a lab in Virginia that is designed to be used as a wound-healing gel. Co. also has under development Vitavent™, an oxygen exchange fluid for facilitating the treatment of lung conditions.
Open the OXBT Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite